Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

BACKGROUND: BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical t...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Lancet Oncol
المؤلفون الرئيسيون: Boorjian, Stephen A, Alemozaffar, Mehrdad, Konety, Badrinath R, Shore, Neal D, Gomella, Leonard G, Kamat, Ashish M, Bivalacqua, Trinity J, Montgomery, Jeffrey S, Lerner, Seth P, Busby, Joseph E, Poch, Michael, Crispen, Paul L, Steinberg, Gary D, Schuckman, Anne K, Downs, Tracy M, Svatek, Robert S, Mashni, Joseph, Lane, Brian R, Guzzo, Thomas J, Bratslavsky, Gennady, Karsh, Lawrence I, Woods, Michael E, Brown, Gordon, Canter, Daniel, Luchey, Adam, Lotan, Yair, Krupski, Tracey, Inman, Brant A, Williams, Michael B, Cookson, Michael S, Keegan, Kirk A, Andriole, Gerald L, Sankin, Alexander I, Boyd, Alan, O’Donnell, Michael A, Sawutz, David, Philipson, Richard, Coll, Ruth, Narayan, Vikram M, Treasure, F Peter, Yla-Herttuala, Seppo, Parker, Nigel R, Dinney, Colin P N
التنسيق: Artigo
اللغة:Inglês
منشور في: 2020
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988888/
https://ncbi.nlm.nih.gov/pubmed/33253641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30540-4
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة